<div id="readability-page-1"><p>NewEdge Advisors LLC boosted its position in shares of  Boston Scientific Corporation (NYSE:BSX - Free Report) by 14.1% in the second quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 109,313 shares of the medical equipment provider's stock after acquiring an additional 13,527 shares during the period. NewEdge Advisors LLC's holdings in Boston Scientific were worth $11,741,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p><div><p><span></span><span>Get <strong>Boston Scientific</strong> alerts:</span></p></div><ul><li>Beware the Death Cross: 3 Stocks Triggering This Spooky Signal</li></ul><p>Several other institutional investors also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of  Boston Scientific during the second quarter worth $2,089,937,000.  Edgewood Management LLC acquired a new position in  Boston Scientific during the 2nd quarter valued at about $746,655,000.  Bessemer Group Inc. raised its stake in  Boston Scientific by 14,391.8% in the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider's stock valued at $313,618,000 after buying an additional 2,899,653 shares during the last quarter.  Vanguard Group Inc. boosted its holdings in  Boston Scientific by 1.9% in the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider's stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares in the last quarter.  Finally, Price T Rowe Associates Inc. MD grew its stake in shares of  Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock worth $1,070,387,000 after acquiring an additional 1,664,108 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Insiders Place Their Bets</h2><p>In other news, Director Ellen M. Zane sold 12,891 shares of the firm's stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company's stock, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 143,095 shares of company stock worth $14,228,950. Corporate insiders own  0.50% of the company's stock. </p><h2>Boston Scientific Price Performance</h2><ul><li>3 Healthcare Stocks Using AI to Drive Growth</li></ul><p>NYSE:BSX opened at $91.60 on Friday. The firm's fifty day moving average is $98.95 and its two-hundred day moving average is $101.73. The firm has a market cap of $135.79 billion, a price-to-earnings ratio of 48.98, a PEG ratio of 1.87 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50. </p><p>Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to analysts' expectations of $4.97 billion. During the same quarter in the previous year, the firm posted $0.63 EPS. The company's revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS.  Research analysts expect that  Boston Scientific Corporation will post 2.85 EPS for the current year. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>3 Biotech Catalysts Present Major Opportunity</li></ul><p>Several equities analysts recently commented on BSX shares. UBS Group increased their price objective on shares of Boston Scientific from $135.00 to $140.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 23rd. Robert W. Baird lifted their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an &#34;outperform&#34; rating in a research note on Wednesday, October 1st. Royal Bank Of Canada  reissued an &#34;outperform&#34; rating and set a $125.00 price objective on shares of Boston Scientific in a report on Monday, September 29th. Cowen  restated a &#34;buy&#34; rating on shares of Boston Scientific in a research note on Thursday. Finally, Wells Fargo &amp; Company boosted their price target on Boston Scientific from $124.00 to $125.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued  a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Buy&#34; and an average price target of $124.43.</p><p><b>View Our Latest Stock Analysis on Boston Scientific</b></p><h2>Boston Scientific Company Profile</h2> (Free Report)<p>Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.</p><h2>See Also</h2><ul><li>Five stocks we like better than Boston Scientific</li><li>3 Defense Stocks Set to Benefit From Increased Military Spending</li><li>3 Recently Downgraded Stocks to Avoid in 2026</li><li>What is a Bond Market Holiday? How to Invest and Trade</li><li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li><li>Most active stocks: Dollar volume vs share volume</li><li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li></ul><p><strong>Want to see what other hedge funds are holding BSX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Boston Scientific Right Now?</h2><p>Before you consider Boston Scientific, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.</p><p>While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>NewEdge Advisors LLC increased its stake in Boston Scientific Corporation by 14.1% in Q2, owning 109,313 shares valued at $11.74 million. Other major investors like Norges Bank and Vanguard Group also adjusted their positions. Insiders sold significant shares recently. Boston Scientific's Q3 earnings exceeded expectations with a 20.3% revenue increase year-over-year. Analysts have raised price targets, indicating positive growth prospects for the company.</p>

NewEdge Advisors LLC Raises Stock Position in Boston Scientific Corporation $BSX